Amneal Pharmaceuticals (NYSE:AMRX) Stock Rating Lowered by Raymond James

Share on StockTwits

Raymond James cut shares of Amneal Pharmaceuticals (NYSE:AMRX) from a strong-buy rating to an outperform rating in a research report report published on Wednesday, The Fly reports. Raymond James currently has $8.50 price objective on the stock, down from their prior price objective of $13.00.

Several other research analysts also recently commented on the stock. Cantor Fitzgerald reissued an overweight rating and set a $130.00 price target (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Zacks Investment Research downgraded shares of Haynes International from a hold rating to a sell rating in a research note on Wednesday, May 8th. SunTrust Banks assumed coverage on shares of Zoetis in a research note on Tuesday, March 19th. They set a hold rating and a $100.00 price target on the stock. Barclays reissued a hold rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. Finally, Piper Jaffray Companies set a $92.00 target price on shares of Wintrust Financial and gave the stock a buy rating in a research note on Monday, July 8th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $14.58.

AMRX stock opened at $3.70 on Wednesday. The stock has a market capitalization of $1.21 billion, a P/E ratio of 3.89, a PEG ratio of 0.25 and a beta of 1.50. Amneal Pharmaceuticals has a one year low of $3.69 and a one year high of $24.48. The business’s 50 day simple moving average is $7.12. The company has a debt-to-equity ratio of 3.44, a current ratio of 2.11 and a quick ratio of 1.37.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.07). The business had revenue of $446.00 million for the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. Amneal Pharmaceuticals’s revenue was up 4.9% compared to the same quarter last year. As a group, equities analysts forecast that Amneal Pharmaceuticals will post 0.91 EPS for the current fiscal year.

In related news, SVP Joseph Todisco purchased 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $148,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Pradeep Bhadauria purchased 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was bought at an average price of $8.48 per share, for a total transaction of $59,360.00. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 41,000 shares of company stock worth $387,300. 26.34% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Bessemer Group Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $34,000. Quantamental Technologies LLC boosted its holdings in shares of Amneal Pharmaceuticals by 34.0% during the 1st quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after buying an additional 1,700 shares in the last quarter. Meeder Asset Management Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 785.6% during the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after buying an additional 10,347 shares in the last quarter. First Mercantile Trust Co. boosted its holdings in shares of Amneal Pharmaceuticals by 40.9% during the 1st quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock valued at $169,000 after buying an additional 3,461 shares in the last quarter. Finally, Amalgamated Bank bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $174,000. Hedge funds and other institutional investors own 36.05% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Read More: Do equity income investments outperform growth and income investments?

The Fly

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.